IO Drugs Assays
I-O has emerged as a powerful therapeutic approach to treat cancer. In our IO Drugs Assay we use Bispecific Antibodies as an additional reactive to generate previous T-Cell activation and potentialize IO Drugs.
- Cell Lysis
- T-Cell activation
- Killing Factor
- Phenotypic Characterization
- Potency Evaluation of IO compounds
- Kinetic Profile
- Trogocytosis
- AML
- CLL
- MM
- Red Blood Cells
- Platelets
- Neutrophils
- AML / CLL / MM Leukemic Cells
- Lymphocytes
- Others
T-Cells Activation
Bispecific
Antibodies
Activated T-Cells
IO Therapy
Autologous
Cryopreserved
Sample
Hematological
Sample
Native Cell
Population
BsAb-mediated
T-Cell Activation Step
IO Drugs: Tumor Lysis
by Activated T-Cells
Cells Retrieval &
FCM Readout
xxxxxxx
xxxxxxx
Hematological
Sample
Sample
- AML
- CLL
- MM
Native Cell
Population
- Red Blood Cells
- Platelets
- Neutrophils
- AML / CLL / MM Leukemic Cells
- Lymphocytes
- Others
BsAb-mediated
T-Cell Activation Step
T-Cells
Activation
Activation
Bispecific
Antibodies
Activated T-Cells
IO Drugs: Tumor Lysis
by Activated T-Cells
IO Therapy
Autologous
Cryopreserved
Sample
Cells Retrieval &
FCM Readout
xxxxxxxx
